DYAI vs MRK vs PFE vs MRNA vs JNJ

For growth investors, Dyadic International, Inc.

(DYAI) is the stronger pick with 20. 6% revenue growth year-over-year, versus -39. 2% for Moderna, Inc. (MRNA). Merck & Co. , Inc. (MRK) offers the better valuation at 15. 4x trailing P/E (21. 9x forward), making it the more compelling value choice. Analysts rate Merck & Co. , Inc. (MRK) a "Buy" — based on 37 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Merck & Co.

, Inc. (MRK) is the cheapest at 15. 4x versus Johnson & Johnson at 38. 4x. On forward P/E, Pfizer Inc. is actually cheaper at 8. 9x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Merck & Co. , Inc. wins at 1. 03x versus Johnson & Johnson's 34. 17x — a reasonable growth-adjusted valuation.

Over the past 5 years, Merck & Co.

, Inc. (MRK) delivered a total return of +70. 2%, compared to -82. 1% for Dyadic International, Inc. (DYAI). Over 10 years, the gap is even starker: MRK returned +166. 5% versus DYAI's -56. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Johnson & Johnson (JNJ) is the lower-risk stock at 0.

06β versus Moderna, Inc. 's 1. 82β — meaning MRNA is approximately 3087% more volatile than JNJ relative to the S&P 500. On balance sheet safety, Moderna, Inc. (MRNA) carries a lower debt/equity ratio of 22% versus 2% for Dyadic International, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Dyadic International, Inc.

(DYAI) is pulling ahead at 20. 6% versus -39. 2% for Moderna, Inc. (MRNA). On earnings-per-share growth, the picture is similar: Moderna, Inc. grew EPS 21. 7% year-over-year, compared to -57. 8% for Johnson & Johnson. Over a 3-year CAGR, DYAI leads at 13. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Merck & Co.

, Inc. (MRK) is the more profitable company, earning 28. 1% net margin versus -166. 2% for Dyadic International, Inc. — meaning it keeps 28. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MRK leads at 36. 2% versus -168. 8% for DYAI. At the gross margin level — before operating expenses — MRK leads at 72. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Merck & Co. , Inc. (MRK) is the more undervalued stock at a PEG of 1. 03x versus Johnson & Johnson's 34. 17x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Pfizer Inc. (PFE) trades at 8. 9x forward P/E versus 21. 9x for Merck & Co. , Inc. — 13. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for MRK: 15. 2% to $129. 31.

In this comparison, PFE (6.

5% yield), MRK (2. 9% yield), JNJ (2. 2% yield) pay a dividend. DYAI, MRNA do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Johnson & Johnson (JNJ) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

06), 2. 2% yield, +132. 3% 10Y return). Moderna, Inc. (MRNA) carries a higher beta of 1. 82 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (JNJ: +132. 3%, MRNA: +161. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: DYAI is a small-cap high-growth stock; MRK is a large-cap deep-value stock; PFE is a mid-cap income-oriented stock; MRNA is a mid-cap quality compounder stock; JNJ is a large-cap quality compounder stock. MRK, PFE, JNJ pay a dividend while DYAI, MRNA do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.